OBJECTIVE: To assess the feasibility and complication rate associated with Subcutaneous Implantable Ports (SIPs) in pediatric cancer patients. METHODS: Ninety nine patients underwent chemo port insertion between January2003 to May 2011 with variety of neoplastic diseases. Data was collected with regards to underlying condition, duration the catheter was in situ and complications during insertion, accessing and removal. Chemoport was inserted either at diagnosis or once optimal conditions were achieved. Ports were placed in internal jugular vein (IJV) or subclavian vein (SCV) under general or local anesthesia under strict aseptic conditions in theatre. RESULTS: A total of 100 ports were placed in 99 patients. The mean duration of the implantable ports was 393 days (range 30-1300). In 49 cases (49%), ports were removed electively, 15 cases (15%) died with port in situ and 36 cases (36%) still have port in situ and receiving chemotherapy without any complications. Complications observed were suspected infection (4%), port fracture (4%), thrombosis of catheter (1%) and blockage (1%). CONCLUSIONS: The use of ports is safe and feasible in Pediatric Oncology patients if strict asepsis guidelines are followed.
OBJECTIVE: To assess the feasibility and complication rate associated with Subcutaneous Implantable Ports (SIPs) in pediatric cancerpatients. METHODS: Ninety nine patients underwent chemo port insertion between January2003 to May 2011 with variety of neoplastic diseases. Data was collected with regards to underlying condition, duration the catheter was in situ and complications during insertion, accessing and removal. Chemoport was inserted either at diagnosis or once optimal conditions were achieved. Ports were placed in internal jugular vein (IJV) or subclavian vein (SCV) under general or local anesthesia under strict aseptic conditions in theatre. RESULTS: A total of 100 ports were placed in 99 patients. The mean duration of the implantable ports was 393 days (range 30-1300). In 49 cases (49%), ports were removed electively, 15 cases (15%) died with port in situ and 36 cases (36%) still have port in situ and receiving chemotherapy without any complications. Complications observed were suspected infection (4%), port fracture (4%), thrombosis of catheter (1%) and blockage (1%). CONCLUSIONS: The use of ports is safe and feasible in Pediatric Oncology patients if strict asepsis guidelines are followed.
Authors: J Mirro; B N Rao; D C Stokes; B A Austin; M Kumar; G V Dahl; M Colten; L Balas; M Rafferty; M Hancock Journal: J Clin Oncol Date: 1989-02 Impact factor: 44.544